DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection.

Author(s): Hsu PI(1), Wu DC(2), Chen WC(1), Tseng HH(3), Yu HC(1), Wang HM(1), Kao SS(1), Lai KH(1), Chen A(4), Tsay FW(5).

Affiliation(s): Author information: (1)Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital and Faculty of Medicine, School of Medicine, National Yang-Ming University, Kaohsiung, Taipei, Taiwan. (2)Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. (3)Department of Pathology, Kaohsiung Veterans General Hospital and National Yang-Ming University, Kaohsiung, Taiwan. (4)Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan. (5)Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital and Faculty of Medicine, School of Medicine, National Yang-Ming University, Kaohsiung, Taipei, Taiwan Cheng Shiu University, Kaohsiung, Taiwan fwchaie@vghks.gov.tw.

Publication date & source: 2014, Antimicrob Agents Chemother. , 58(10):5936-42

With the rising prevalence of antimicrobial resistance, the failure rate of the standard triple therapy for Helicobacter pylori infection is increasing. Sequential therapy and concomitant therapy have been recommended to replace standard triple therapy for H. pylori eradication in regions with high clarithromycin resistance. The aim of this prospective, randomized, and controlled study was to simultaneously assess the efficacies of 10-day sequential and 7-day concomitant therapies versus a 7-day standard triple therapy for treating H. pylori infection. Consecutive H. pylori-infected subjects were randomly assigned to a 7-day standard triple therapy (pantoprazole, clarithromycin, and amoxicillin for 7 days), a 10-day sequential therapy (pantoprazole and amoxicillin for 5 days, followed by pantoprazole, clarithromycin, and metronidazole for a further 5 days), or a 7-day quadruple therapy (pantoprazole, clarithromycin, amoxicillin, and metronidazole for 7 days). H. pylori status was confirmed 6 weeks after therapy. Three hundred seven H. pylori-infected participants were randomized to receive triple (n = 103), sequential (n = 102), or concomitant (n = 102) therapies. The eradication rates by an intention-to-treat analysis in the three treatment groups were 81.6% (95% confidence interval [CI], 74.1% to 89.0%), 89.2% (95% CI, 83.2% to 95.2%), and 94.1% (95% CI, 89.5% to 98.7%). The seven-day concomitant therapy had a higher eradication rate than did the 7-day triple therapy (difference, 12.5%; 95% CI, 3.7% to 21.3%). There were no significant differences in the eradication rates between the sequential and standard triple therapies. All three treatments exhibited similar frequencies of adverse events (8.7%, 8.8%, and 13.7%, respectively) and drug compliance (99.0%, 98.0%, and 100.0%, respectively). In conclusion, the seven-day concomitant therapy is superior to the 7-day standard triple therapy for H. pylori eradication. Additionally, it is less complex than the 10-day sequential therapy because the drugs are not changed halfway through the treatment course. (This study has been registered at ClinicalTrials.gov under registration no. NCT1769365.).

Page last updated: 2015-08-10

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017